Could a simple Beta-Blocker stop a second cardiac arrest?

NCT ID NCT07405229

Recruiting now Disease control Sponsor: Bo Gregers Winkel Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether low-dose beta-blockers can reduce dangerous heart rhythms in people who have survived a cardiac arrest with no clear cause. About 218 participants will receive one of several beta-blockers and be followed for up to 3 years. The goal is to see if this treatment lowers the need for shocks from an implanted defibrillator.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: beta-blocker (propranolol, nadolol, atenolol, bisoprolol, or metoprolol)
What this could lead to: If beta-blockers work, this could give doctors a standard way to lower the chance of repeat cardiac arrest in people with unexplained ventricular fibrillation.
What could go wrong: This is a relatively small, early-phase study. Beta-blockers may not reduce arrhythmias in these patients, and side effects like fatigue or low blood pressure could occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC ARREST, OUT-OF-HOSPITAL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiac arrest Out-of-Hospital Cardiac Arrest paroxysmal familial ventricular fibrillation Paroxysmal ventricular fibrillation ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC ARREST, OUT-OF-HOSPITAL IDIOPATHIC VENTRICULAR FIBRILLATION

Contacts and locations

Locations

Odense University Hospital
NOT_YET_RECRUITING

Odense, 5000, Denmark
The Heart Center, Rigshospitalet
RECRUITING

Copenhagen, Dr., 2100, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.